Alvotech INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (ALVO)

Core Viewpoint - Alvotech is under investigation for potential violations of federal securities laws following a significant decline in its stock price after receiving a complete response letter from the FDA regarding its biologics license application for AVT05 [1][3]. Group 1: Company Investigation - Kirby McInerney LLP is investigating potential claims against Alvotech for possible unlawful business practices [1]. - The investigation is focused on whether Alvotech violated federal securities laws [1]. Group 2: Recent Developments - On November 3, 2025, Alvotech received a complete response letter from the FDA related to a failed facility inspection that took place in July 2025 [3]. - Following this news, Alvotech's share price dropped by $2.62, representing a decline of approximately 34.25%, from $7.65 on October 31, 2025, to $5.03 on November 3, 2025 [3].